{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:29:26Z","timestamp":1777613366729,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.taap.2011.11.018","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T23:08:29Z","timestamp":1323385709000},"page":"351-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Synergism between arsenite and proteasome inhibitor MG132 over cell death in myeloid leukaemic cells U937 and the induction of low levels of intracellular superoxide anion"],"prefix":"10.1016","volume":"258","author":[{"given":"Tom\u00e1s","family":"Lombardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Cavaliere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana N.","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kornblihtt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elida M.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo A.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2011.11.018_bb0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jlb.55.2.253","article-title":"Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells","volume":"55","author":"Carter","year":"1994","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.taap.2011.11.018_bb0010","series-title":"Casarett and Doull's toxicology: The Basic Science of Poisons","author":"Casarett","year":"2008"},{"key":"10.1016\/j.taap.2011.11.018_bb0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1593\/tlo.08202","article-title":"Caffeic acid phenylethyl ester and MG-132 have apoptotic and antiproliferative effects on leukemic cells but not on normal mononuclear cells","volume":"2","author":"Cavaliere","year":"2009","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.taap.2011.11.018_bb0020","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.imbio.2005.03.001","article-title":"Ligaria cuneifolia flavonoid fractions modulate cell growth of normal lymphocytes and tumor cells as well as multidrug resistant cells","volume":"209","author":"Cerda Zolezzi","year":"2005","journal-title":"Immunobiology"},{"key":"10.1016\/j.taap.2011.11.018_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08262.x","article-title":"Development of target-specific treatments in multiple myeloma","volume":"151","author":"Chanan-Khan","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.taap.2011.11.018_bb0030","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","article-title":"In vitro studies on cellular and molecular mechanisms of arsenic trioxide As2O3 in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha\/PML proteins","volume":"88","author":"Chen","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.taap.2011.11.018_bb0035","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/cdd.2009.49","article-title":"Superoxide is the major reactive oxygen species regulating autophagy","volume":"16","author":"Chen","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.taap.2011.11.018_bb0040","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou\u2013Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2011.11.018_bb0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.taap.2011.11.018_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.moh.0000148552.93303.45","article-title":"Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies","volume":"12","author":"Chou","year":"2005","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.taap.2011.11.018_bb0120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2011.11.018_bb0055","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3892\/ol_00000083","article-title":"Arsenic trioxide enhances the cytotoxic effect of thalidomide in a KG-1a human acute mylogenous leukemia cell line","volume":"1","author":"Girgis","year":"2010","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.taap.2011.11.018_bb0060","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jcb.20337","article-title":"Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60","volume":"94","author":"Han","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.taap.2011.11.018_bb0065","first-page":"794","article-title":"Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line","volume":"16","author":"He","year":"2008","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.taap.2011.11.018_bb0070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/cyto.990150411","article-title":"Evaluation of methods for measuring cellular glutathione content using flow cytometry","volume":"15","author":"Hedley","year":"1994","journal-title":"Cytometry"},{"key":"10.1016\/j.taap.2011.11.018_bb0075","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1073\/pnas.0813280106","article-title":"Long-term efficacy and safety of all-trans retinoic acid\/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia","volume":"106","author":"Hu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2011.11.018_bb0080","doi-asserted-by":"crossref","first-page":"7436","DOI":"10.1158\/0008-5472.CAN-04-2628","article-title":"Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines","volume":"65","author":"Izeradjene","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2011.11.018_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11010-007-9663-7","article-title":"Caffeic acid phenethyl ester induces mitochondria-mediated apoptosis in human myeloid leukemia U937 cells","volume":"310","author":"Jin","year":"2008","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.taap.2011.11.018_bb0090","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood.V94.6.2102","article-title":"Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway","volume":"94","author":"Jing","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.taap.2011.11.018_bb0095","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1182\/blood-2009-03-211821","article-title":"Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia\/lymphoma (ATL)","volume":"113","author":"Kchour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.taap.2011.11.018_bb0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jcp.21523","article-title":"PML\/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase","volume":"217","author":"Li","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.taap.2011.11.018_bb0105","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MOH.0b013e328302c7f4","article-title":"NF-kappaB in the pathogenesis and treatment of multiple myeloma","volume":"15","author":"Li","year":"2008","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.taap.2011.11.018_bb0110","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2004.04940.x","article-title":"Hydrogen peroxide in the Burkitt's lymphoma cell line Raji provides protection against arsenic trioxide-induced apoptosis via the phosphoinositide-3 kinase signalling pathway","volume":"125","author":"Lu","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.taap.2011.11.018_bb0115","doi-asserted-by":"crossref","first-page":"20416","DOI":"10.1074\/jbc.M609582200","article-title":"Glutathione is recruited into the nucleus in early phases of cell proliferation","volume":"282","author":"Markovic","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2011.11.018_bb0125","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1124\/jpet.104.080713","article-title":"Arsenite delays progression through each cell cycle phase and induces apoptosis following G2\/M arrest in U937 myeloid leukemia cells","volume":"313","author":"McCollum","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2011.11.018_bb0130","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12032-009-9294-9","volume":"27","author":"Momeny","year":"2010","journal-title":"Med. Oncol."},{"key":"10.1016\/j.taap.2011.11.018_bb0135","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1470-2045(08)70304-8","article-title":"New drugs in multiple myeloma: mechanisms of action and phase I\/II clinical findings","volume":"9","author":"Ocio","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.taap.2011.11.018_bb0140","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2567.2008.02806.x","article-title":"MG132 proteasome inhibitor modulates proinflammatory cytokines production and expression of their receptors in U937 cells: involvement of nuclear factor-kappaB and activator protein-1","volume":"124","author":"Ortiz-Lazareno","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.taap.2011.11.018_bb0145","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/10428190903486212","article-title":"Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines","volume":"51","author":"Peng","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.taap.2011.11.018_bb0150","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.bcp.2008.02.007","article-title":"Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines","volume":"75","author":"Ramos","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2011.11.018_bb0155","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/jcp.20806","article-title":"Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis","volume":"209","author":"Ramos","year":"2006","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.taap.2011.11.018_bb0160","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1182\/blood-2004-07-2802","article-title":"Pharmacologic inhibitors of PI3K\/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells","volume":"105","author":"Ramos","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.taap.2011.11.018_bb0165","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2011.11.018_bb0170","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.23855","article-title":"Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia","volume":"113","author":"Roboz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.taap.2011.11.018_bb0175","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/157489206778776925","article-title":"Bortezomib in the treatment of cancer","volume":"1","author":"Roccaro","year":"2006","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.taap.2011.11.018_bb0180","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1124\/jpet.110.168344","article-title":"Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines","volume":"335","author":"Sanchez","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2011.11.018_bb0185","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.exppara.2009.04.012","article-title":"Flow cytometric determination of intracellular non-protein thiols in Leishmania promastigotes using 5-chloromethyl fluorescein diacetate","volume":"122","author":"Sarkar","year":"2009","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.taap.2011.11.018_bb0190","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/cncr.25686","article-title":"A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"117","author":"Sekeres","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.taap.2011.11.018_bb0215","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.taap.2010.02.012","article-title":"Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells","volume":"244","author":"Sumi","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2011.11.018_bb0195","first-page":"1022","article-title":"HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro","volume":"27","author":"Sun","year":"2007","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.taap.2011.11.018_bb0200","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/jcp.20153","article-title":"Phosphoinositide 3-kinase\/Akt involvement in arsenic trioxide resistance of human leukemia cells","volume":"202","author":"Tabellini","year":"2005","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.taap.2011.11.018_bb0205","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/1871520611009060504","article-title":"Combination therapy with arsenic trioxide for hematological malignancies","volume":"10","author":"Takahashi","year":"2010","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.taap.2011.11.018_bb0210","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3565(24)29450-7","article-title":"Drug synergism: its detection and applications","volume":"298","author":"Tallarida","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2011.11.018_bb0220","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood.V92.5.1497","article-title":"Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner","volume":"92","author":"Wang","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.taap.2011.11.018_bb0225","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/sj.leu.2404735","article-title":"Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta","volume":"21","author":"Yan","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2011.11.018_bb0230","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2009.06.038","article-title":"The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation","volume":"288","author":"Zanotto-Filho","year":"2010","journal-title":"Cancer Lett."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X11004546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X11004546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:39:56Z","timestamp":1758573596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X11004546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0041008X11004546"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2011.11.018","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergism between arsenite and proteasome inhibitor MG132 over cell death in myeloid leukaemic cells U937 and the induction of low levels of intracellular superoxide anion","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2011.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}